Biomarkers for Prediction of Central Venous Catheter Related-Thrombosis in Patients With Hematological Malignancies

Boersma, Rinske; Hamulyák, Karly; Oerle, René van; Tuinenburg, A.; Cate‐Hoek, Arina J. ten; Schouten, Harry C.

doi:10.1177/1076029615579098

Cited by 8 publications

(20 citation statements)

References 37 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who went on to develop thrombosis had higher factor VIII (FVIII) immediately following CVC placement (203 ± 62% vs 166 ± 59%, p = 0.023). [21]…”

Section: Resultsmentioning

confidence: 99%

“…They reported mean protein S antigen levels of 100% ± 34 in patients with CVC-related thrombosis and 93% ± 29 (p = 0.417) in patients with vs without VTE. [21] Aue et al, previously described, examined median levels of protein S and found no overlap between 5 (of 32) patients with DVT and an additional 5 with low protein S (<55%) and no patients with low protein C (<59%). [20] Auwerda et al studied protein C and S levels in 135 adult patients with untreated multiple myeloma.…”

Section: Resultsmentioning

confidence: 99%

“…Boersma et al, described above, did not find a significant difference in mean PAI-I levels between patients with CVC-associated thrombosis (12.2 IU/mL, IQR 3.5–22.7) and those without (4.9 IU/mL, 1.7–10.2) (p = 0.062) but did find a higher rate of PAI > 12.2 IU/mL among patients with thrombosis (8/15) vs without (34/153) (p = 0.08). [21] Mitrovic et al studied 59 patients with APL and found the PAI-1 4G/5G variant to be present in 11.1% of patients with VTE and 56% of patients without (p = 0.04), 55.6% and 20.0% of patients, respectively, were found to be homozygous for 4G/4G. PAI-1 levels were not reported.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review

Bannow

Konkle

2018

Thrombosis Research

View full text Add to dashboard Cite

The most studied biomarkers, d-dimer and fibrinogen, demonstrated some degree of efficacy in identifying high-risk patients at levels >4.0 mg/L or <1.0 g/L respectively. Additional markers which demonstrated promise included thrombin generation, mean platelet volume, soluble VEGF, soluble P-selectin and extracellular vesicles. Other biomarkers reviewed, which did not consistently demonstrate significant associations with VTE included prothrombin fragments F1 + 2, factor VIII, protein C, protein S, von Willebrand antigen and activity, antithrombin, thrombin antithrombin complex, antiphospholopid antibody, plasminogen activator inhibitor, tissue factor pathway inhibitor and several variants associated with known hypercoagulable states (factor V Leiden, prothrombin gene variant, methylenetetrahydrofolate reductase variant). Data to support any of the biomarkers discussed here in routine clinical decision-making are currently lacking, but additional investigation in clinical studies, ideally in combination with clinical factors known to be associated with increased thrombotic risk, is warranted.

show abstract

“…Patients who went on to develop thrombosis had higher factor VIII (FVIII) immediately following CVC placement (203 ± 62% vs 166 ± 59%, p = 0.023). [21]…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review

Bannow

Konkle

2018

Thrombosis Research

View full text Add to dashboard Cite

show abstract

“…Several adult studies demonstrated the association of elevated TG parameters with the occurrence of the first VTE event (OR = 1.7) and with recurrence of unprovoked VTE (ORs = 1.6‐4.6) . Similarly, FVIII has shown prospective predictive potential in a subset of adults, both in association with CVC and without CVC (adjusted OR = 3), with FVIII levels >200%. None of these studies evaluated the value of combining clinical prediction tools and biomarkers, but several compared the two approaches in the evaluation of at‐risk adults …”

Section: Discussionmentioning

confidence: 99%

Promising biomarkers for the prediction of catheter‐related venous thromboembolism in hospitalized children: An exploratory study

Nossair

Mahajerin

Hoang

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Pediatric venous thromboembolism (VTE) has increased over the past 10 years, with central venous catheters (CVC) being the strongest risk factor. Current tools are not sufficient to predict VTE risk. The utility of biomarkers in predicting CVC-related VTE has been minimally explored. Our objective is to determine the utility of microparticles (MPs), factor VIII (FVIII) activity, and thrombin generation (TG) in prospectively predicting VTE occurrence in hospitalized children with CVCs. Procedure:In this nested case-control pilot study, consecutive hospitalized children needing CVC placement (1 month to 21 years) were enrolled. Venous samples were collected prior to or within 24 h of CVC placement. MPs were measured using factor Xa initiated clot-based assay. FVIII was measured using a one-stage clot-based assay. TG was measured using calibrated automated thrombogram.Results: There were three CVC-related VTE events (7%) in our cohort of 42 subjects. Xa clotting time (XaCT) ratio was lower (0.68 ± 0.07 vs 0.95 ± 0.21, P = .4), while FVIII (461 ± 120 vs 267 ± 130, P = .02), peak thrombin (418 ± 89 vs 211 ± 101, P = .001), endogenous thrombin potential (ETP) (1828 ± 485 vs 1282 ± 394, P = .03), and velocity index (VI) (182 ± 28 vs 75 ± 53, P = .001) were higher in subjects with CVC-related VTE compared to those without CVC-related VTE. Sensitivity/specificity analysis revealed optimal cutoff values for XaCT ratio (0.75), FVIII (370), ETP (1680), peak (315), and VI (130), with receiver operating characteristic area under the curve values >0.9.Conclusion: MPs, FVIII, and TG can potentially predict pediatric CVC-related VTE in a prospective fashion. Stratification according to VTE risk may aid in guiding preventative efforts in future studies.

show abstract

“…In critically ill adults, d‐dimer has also been shown to be predictive of DVT . Other proteins, such as thrombin‐antithrombin complex (TAT), prothrombin fragment 1+2 (PF1+2), plasminogen activator inhibitor‐1, and soluble P‐selectin, have been shown to be associated with incident DVT in adults . Except for d‐dimer, none of these has been tested to predict DVT in children …”

Section: Introductionmentioning

confidence: 99%

Protein biomarkers for incident deep venous thrombosis in critically ill adolescents: An exploratory study

Tala

Polikoff

Pinto

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background There are no tests to identify critically ill children at high risk of deep venous thrombosis (DVT). In this exploratory study, we aimed to identify proteins that are associated with incident DVT in critically ill adolescents. Procedure Plasma samples were obtained from critically ill adolescents within 24 hours after initiation of cardiopulmonary support. The adolescents were followed with ultrasound to detect the development of DVT of the lower extremity and clinically for bleeding. Thrombin‐antithrombin complex and prothrombin fragment 1+2 were measured using immunosorbent assays, whereas procoagulation and anticoagulation factors were measured using multiplex assays. Plasma samples were also analyzed using SOMAscan, an aptamer‐based capture assay. The associations between DVT and the log‐transformed level of the proteins were assessed using logistic regression adjusting for the presence of femoral venous catheter and severity of illness. Associations were expressed as odds ratio (OR) for every log‐fold increase in level of the protein with 95% confidence interval (CI). Results Plasma from 59 critically ill adolescents, of whom 9 developed incident DVT, was analyzed. The median age of the adolescents was 15.1 years (interquartile range, 14.0‐16.7 years). Higher levels of thrombin‐antithrombin complex (OR: 31.54; 95% CI: 2.09‐475.92) and lower levels of factor XIII (OR: 0.03; 95% CI: 0.002‐0.44) were associated with DVT. CD36, MIC‐1, and EpoR were marginally associated with DVT. Only factor XIII was associated with clinically relevant bleeding (OR: 0.27; 95% CI: 0.08‐0.97). Conclusions We identified candidate protein biomarkers for incident DVT. We plan to validate our findings in adequately powered studies.

show abstract

Biomarkers for Prediction of Central Venous Catheter Related-Thrombosis in Patients With Hematological Malignancies

Cited by 8 publications

References 37 publications

Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review

Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review

Promising biomarkers for the prediction of catheter‐related venous thromboembolism in hospitalized children: An exploratory study

Protein biomarkers for incident deep venous thrombosis in critically ill adolescents: An exploratory study

Contact Info

Product

Resources

About